Anika Therapeutics ANIK
$ 17.55
2.15%
Quarterly report 2024-Q3
added 11-04-2024
Anika Therapeutics Balance Sheet 2011-2024 | ANIK
Annual Balance Sheet Anika Therapeutics
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-46 M | -57.5 M | -75.1 M | - | -135 M | -89 M | -133 M | -104 M | -111 M | -100 M | -63.3 M | -34.5 M | -24.6 M |
Long Term Debt |
26.9 M | 28.8 M | 19.2 M | - | - | - | - | - | - | - | - | 8 M | 9.6 M |
Long Term Debt Current |
- | - | - | - | - | - | - | - | - | - | - | 1.6 M | 1.6 M |
Total Non Current Liabilities |
- | - | - | - | 26.1 M | 4.09 M | 6.05 M | 8.67 M | 7.62 M | 9.93 M | 11.1 M | 18.7 M | 23.5 M |
Total Current Liabilities |
31.1 M | 27.9 M | 29.8 M | 36.9 M | 16.3 M | 11.3 M | 13.1 M | 8.8 M | 17.3 M | 5.97 M | 9.28 M | 14.5 M | 14.5 M |
Total Liabilities |
- | - | - | - | 42.3 M | 15.4 M | 19.1 M | 17.5 M | 24.9 M | 15.9 M | 20.4 M | 33.1 M | 38.1 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | 24.5 K | 180 K | 2.88 M | 2.87 M |
Retained Earnings |
128 M | 211 M | 226 M | 221 M | 245 M | 218 M | 200 M | 168 M | 136 M | 105 M | 66.6 M | 46 M | 34.3 M |
Total Assets |
271 M | 349 M | 348 M | 366 M | 331 M | 279 M | 283 M | 240 M | 236 M | 194 M | 156 M | 142 M | 133 M |
Cash and Cash Equivalents |
72.9 M | 86.3 M | 94.4 M | 95.8 M | 157 M | 89 M | 133 M | 104 M | 111 M | 100 M | 63.3 M | 44.1 M | 35.8 M |
Book Value |
271 M | 349 M | 348 M | 366 M | 288 M | 264 M | 263 M | 223 M | 211 M | 178 M | 136 M | 109 M | 94.8 M |
Total Shareholders Equity |
212 M | 286 M | 287 M | 272 M | 288 M | 264 M | 263 M | 223 M | 211 M | 178 M | 136 M | 109 M | 94.8 M |
All numbers in USD currency
Quarterly Balance Sheet Anika Therapeutics
2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
25.2 M | 25.8 M | 26.3 M | 26.9 M | - | 27.8 M | 28.3 M | 28.8 M | 29.2 M | - | 18.8 M | 19.2 M | 19.6 M | 20.1 M | 20.5 M | 356 K | 25 M | 50 M | 468 K | - | 21.4 M | - | 21.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.8 M | 7.2 M | 7.6 M | 8 M | 8 M | 8 M | 8 M | 9.6 M | 9.6 M | 9.6 M | 9.6 M |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 52 K | 74 K | - | - | - | - | - | - | - | - | - | - | 33.9 K | 35.9 K | 140 K | 24.5 K | 12.9 K | 24.5 K | 24.5 K | 180 K | 180 K | 180 K | 180 K | 2.88 M | 2.88 M | 2.88 M | 2.88 M | 2.87 M | 2.87 M | 2.87 M | 2.87 M |
Retained Earnings |
93.5 M | 123 M | 124 M | 128 M | - | 198 M | 200 M | 211 M | 216 M | - | 223 M | 226 M | 231 M | 231 M | 224 M | 221 M | 221 M | 221 M | 221 M | 245 M | 245 M | 245 M | 245 M | 218 M | 218 M | 218 M | 218 M | 200 M | 200 M | 200 M | 200 M | 168 M | 168 M | 168 M | 168 M | 136 M | 136 M | 136 M | 136 M | 105 M | 105 M | 105 M | 105 M | 66.6 M | 66.6 M | 66.6 M | 66.6 M | 46 M | 46 M | 46 M | 46 M | 34.3 M | 34.3 M | 34.3 M | 34.3 M |
Total Assets |
231 M | 263 M | 264 M | 271 M | - | 329 M | 339 M | 349 M | 348 M | - | 342 M | 348 M | 353 M | 363 M | 362 M | 366 M | 366 M | 366 M | 366 M | 331 M | 331 M | 331 M | 331 M | 279 M | 279 M | 279 M | 279 M | 283 M | 283 M | 283 M | 283 M | 240 M | 240 M | 240 M | 240 M | 236 M | 236 M | 236 M | 236 M | 193 M | 194 M | 194 M | 194 M | 156 M | 156 M | 156 M | 156 M | 142 M | 142 M | 142 M | 142 M | 133 M | 133 M | 133 M | 133 M |
Cash and Cash Equivalents |
62.4 M | 62.8 M | 68.6 M | 72.9 M | - | 65.1 M | 79.7 M | 86.3 M | 87.8 M | - | 90.3 M | 94.4 M | 91 M | 97.2 M | 94.6 M | 95.8 M | 95.8 M | 95.8 M | 95.8 M | 157 M | 157 M | 157 M | 157 M | 89 M | 89 M | 89 M | 89 M | 133 M | 133 M | 133 M | 133 M | 104 M | 104 M | 104 M | 104 M | 111 M | 111 M | 111 M | 111 M | 100 M | 100 M | 100 M | 100 M | 63.3 M | 63.3 M | 63.3 M | 63.3 M | 44.1 M | 44.1 M | 44.1 M | 44.1 M | 35.8 M | 35.8 M | 35.8 M | 35.8 M |
Book Value |
231 M | 263 M | 264 M | 271 M | - | 329 M | 339 M | 349 M | 348 M | - | 342 M | 348 M | 353 M | 363 M | 362 M | 366 M | 366 M | 366 M | 366 M | 331 M | 331 M | 331 M | 331 M | 279 M | 279 M | 279 M | 279 M | 283 M | 283 M | 283 M | 283 M | 240 M | 240 M | 240 M | 240 M | 236 M | 236 M | 236 M | 236 M | 193 M | 194 M | 194 M | 194 M | 156 M | 156 M | 156 M | 156 M | 142 M | 142 M | 142 M | 142 M | 133 M | 133 M | 133 M | 133 M |
Total Shareholders Equity |
180 M | 210 M | 209 M | 212 M | 270 M | 274 M | 278 M | 286 M | 285 M | 286 M | 286 M | 287 M | 290 M | 287 M | 277 M | 272 M | 272 M | 272 M | 272 M | 288 M | 288 M | 288 M | 288 M | 264 M | 264 M | 264 M | 264 M | 263 M | 263 M | 263 M | 263 M | 223 M | 223 M | 223 M | 223 M | 211 M | 211 M | 211 M | 211 M | 178 M | 178 M | 178 M | 178 M | 136 M | 136 M | 136 M | 136 M | 109 M | 109 M | 109 M | 109 M | 94.8 M | 94.8 M | 94.8 M | 94.8 M |
All numbers in USD currency